ISSN2320-2882
Impact Factor9.17
UGC ParametersAligned
Low Cost₹1501 / $59
CrossRefDOI
ESTD2013
Peer ReviewTransparent
AccessOpen
Submission: Always Open
Paper Title
"Atogepant: A Novel Therapeutic Agent in the Management of Migraine"
Authors
Dr. Garlapati Usha Kiran , Maareedu Mahesh , Loya Pavan kumar , Kankanala Uma Satya Manikanta , Gollamudi Nehemiah
Keywords
Migraine, Atogepant, CGRP receptor antagonist, Episodic migraine prevention, Pathophysio logy, Pharmacokinetics, Neurogenic inflammation, Adverse effects, Drug interactions, Personalized migraine therapy
Abstract
Migraine is a common neurological condition that can really take a toll on people's quality of life and productivity around the globe. It's marked by recurring headaches that often come with nausea, sensitivity to light, and sensitivity to sound. Traditional preventive treatments, like beta-blockers and antiepileptics, often fall short in terms of effectiveness and tolerability, which is why there's a need for new options. Enter atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist that's making waves in the world of migraine prevention. It got the green light from the FDA in 2021, followed by approvals from Health Canada and the EMA, making it the first oral CGRP antagonist specifically designed for preventing migraines. Atogepant is quickly absorbed, spreads widely in the body, and is mainly broken down by CYP3A4, boasting a half-life of about 11 hours, which allows for once-daily dosing. It works by blocking CGRP-induced vasodilation and neurogenic inflammation, helping to cut down on the frequency and intensity of migraines. Clinical trials have shown it effectively reduces the number of migraine days each month, with some common side effects like constipation, nausea, and fatigue. All in all, atogepant offers a safe, effective, and convenient oral solution, marking a big step forward in personalized migraine management.
Full Paper, Downloads & Preview
How To Cite
Choose the style your journal or department asks for, then copy it. Every version below is generated from this paper's own record.
IJCRT — journal style
""Atogepant: A Novel Therapeutic Agent in the Management of Migraine"", IJCRT - International Journal of Creative Research Thoughts (www.ijcrt.org), ISSN:2320-2882, Vol.13, Issue 8, page no.f350-f358, August 2025, Available :https://ijcrt.org/papers/IJCRT2508611.pdf
APA — 7th edition
Kiran, G. U., Mahesh, M., kumar, L. P., Manikanta, K. U. S., & Nehemiah, G. (2025). "Atogepant: A Novel Therapeutic Agent in the Management of Migraine". International Journal of Creative Research Thoughts, 13(8), f350-f358. https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611
MLA — 9th edition
Kiran, Garlapati Usha, et al. ""Atogepant: A Novel Therapeutic Agent in the Management of Migraine"." International Journal of Creative Research Thoughts, vol. 13, no. 8, 2025, pp. f350-f358, https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611.
Chicago — 17th, bibliography
Kiran, Garlapati Usha, et al. ""Atogepant: A Novel Therapeutic Agent in the Management of Migraine"." International Journal of Creative Research Thoughts 13, no. 8 (2025): f350-f358. https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611.
Harvard — author–date
Kiran, G.U. et al. (2025) '"Atogepant: A Novel Therapeutic Agent in the Management of Migraine"', International Journal of Creative Research Thoughts, 13(8), pp. f350-f358. Available at: https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611
IEEE — numbered reference
G. U. Kiran, M. Mahesh, L. P. kumar, K. U. S. Manikanta and G. Nehemiah, ""Atogepant: A Novel Therapeutic Agent in the Management of Migraine"," IJCRT, vol. 13, no. 8, pp. f350-f358, Aug. 2025.
Vancouver — biomedical
Kiran GU, Mahesh M, kumar LP, Manikanta KUS, Nehemiah G. "Atogepant: A Novel Therapeutic Agent in the Management of Migraine". IJCRT. 2025 Aug;13(8):f350-f358.
AMA — 11th edition
Kiran GU, Mahesh M, kumar LP, Manikanta KUS, Nehemiah G. "Atogepant: A Novel Therapeutic Agent in the Management of Migraine". IJCRT. 2025;13(8):f350-f358. Accessed at https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611
BibTeX — Zotero, Mendeley, LaTeX
@article{IJCRT2508611,
author = {Garlapati Usha Kiran and Maareedu Mahesh and Loya Pavan kumar and Kankanala Uma Satya Manikanta and Gollamudi Nehemiah},
title = {"Atogepant: A Novel Therapeutic Agent in the Management of Migraine"},
journal = {International Journal of Creative Research Thoughts},
volume = {13},
number = {8},
pages = {f350-f358},
year = {2025},
month = {August},
issn = {2320-2882},
url = {https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611}
}
RIS — EndNote, RefWorks
TY - JOUR
AU - Kiran, Garlapati Usha
AU - Mahesh, Maareedu
AU - kumar, Loya Pavan
AU - Manikanta, Kankanala Uma Satya
AU - Nehemiah, Gollamudi
TI - "Atogepant: A Novel Therapeutic Agent in the Management of Migraine"
T2 - International Journal of Creative Research Thoughts
JA - IJCRT
VL - 13
IS - 8
PY - 2025
SN - 2320-2882
UR - https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611
SP - f350-f358
ER -
Issue
Volume 13 Issue 8,
August-2025
Pages : f350-f358
Article Information
- Pages
- f350-f358
- Published
- August 2025
- Registration ID
- IJCRT_292790
- Published Paper ID
- IJCRT2508611
- Research Area
- Science and Technology
- Author Type
- Indian Author
- Location
- India
- Peer Review
- Request Peer Review Report
- Licence
- CC BY 4.0 · Open Access
- ISSN & Impact Factor
- 2320-2882 · IF 9.17
- Downloads
- 257
- Permanent Link
- https://ijcrt.org/viewpaperforall.php?paper=IJCRT2508611
- Published Paper PDF
- https://ijcrt.org/papers/IJCRT2508611.pdf
Summarise this Paper with AI
Opens your assistant with a prepared prompt. AI summaries can be incomplete or wrong — read the full paper before citing it.
Author Services
Certificates, printed copies and official reports for this paper
Published authors can request a hard copy of their certificate or of the printed journal, and obtain the transparent peer review and plagiarism reports for this article — each issued against this paper’s registration record.
Registration ID IJCRT_292790Printed copies
Hard Copy of CertificatePrinted certificate for each author, posted to you.
Hard Copy of JournalA bound printed copy of the issue this paper appears in.
Reports & recognition
Transparent Peer Review Report
The reviewer comments and decisions behind this article.
Turnitin Plagiarism Report
The similarity check run on this manuscript.
Best Paper Nomination
Put this article forward for the issue’s best paper award.
Requests are verified against the registration ID of this article.
About Publisher
International Journal of Creative Research Thoughts
Published by IJCRT Publication
2320-2882
ISSN
9.17
Impact Factor
2013
ESTD Year
Open
Access
Impact Factor 9.17, calculated from Google Scholar citation data — see how it is worked out.
An international scholarly open access journal: peer-reviewed, refereed, multidisciplinary, monthly and multilingual, with Crossref DOI registration, rich metadata and a citation generator. Verified indexing & discovery records.
IJCRT is a Transparent, Peer-Reviewed, Open Access Journal (Refereed Journal). Following the discontinuation of UGC and UGC-CARE journal listing, IJCRT is aligned with UGC’s Suggested Parameters for Choosing Peer-Reviewed Journals. UGC Public Notice
Licence
© 2025 — Authors hold the copyright of this article.
This work is licensed under a
Creative Commons Attribution 4.0 International License
and The Open Definition.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0),
which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Disclaimer:
The content, data and findings in this article are based on the authors’ research and have been
peer-reviewed for academic purposes only. Readers are advised to verify all information before practical
or commercial use. The journal and its editorial board are not liable for any errors, losses or
consequences arising from its use.
Declarations
Funding
No external funding was received for this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Acknowledgements
The authors would like to thank the reviewers and the editorial board of International Journal of Creative Research Thoughts for their careful reading and constructive comments, and all colleagues who supported the preparation of this manuscript.
About the Journal
9.17Impact Factor
UGC AlignedSuggested Parameters
TransparentPeer Review
Open AccessNo Paywall
CrossrefDOI Available
Monthly12 Issues / Year
Since 2013Established
2320-2882ISSN
How Publication Works
1Submit Your PaperOnline or by email. A registration ID is issued straight away.
2Transparent Peer ReviewDouble-blind review by subject experts, reported openly.
3AcceptanceThe result reaches you by email and SMS against your registration ID.
4Published Open AccessFree to read worldwide, with certificate and letter ready to download.
Article Impact
37Views
20Downloads
57Total reads
Aug 2025Published
Published · 413 days ago
Today · last read today
1.9 views and 1.0 downloads per day over 20 days counted.
Counts exclude identified crawler traffic and repeat hits from the same reader within 30 minutes. Downloads reached directly through a search engine or an existing citation link are not included, so the figure is a conservative count of activity through this site. Full statistics
Discovery & Indexing
Find this paper on search engines and scholarly indexes, and check the journal’s verified records.
Find this paperSearch
Google ScholarExact-title search, with citing articles once indexed.Search
CrossrefMetadata search across all Crossref records.Search
Semantic ScholarAI-powered literature search.Search- BASEBASEBielefeld Academic Search Engine — open-access harvester.Search
ResearchGateResearch network publication search.Search
Journal recordsVerified
“Search” opens a live search for this paper; “Verified” opens a journal record checked on the Indexing & Discovery page. Third-party services index at their own discretion, often several weeks after publication.
